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ABSTRACT
Background & Aims: The progression of nonalcoholic fatty liver disease (NAFLD) into severe 
histological forms (steatohepatitis-NASH) is paralleled by the occurrence of complex molecular 
processes. Mitochondrial dysfunction is a hallmark feature of advanced disease. Mitochondrially-
encoded cytochrome B (cytochrome b, MT-CYB)—a member of the oxidative phosphorylation 
system, is a key component of the respirasome supercomplex. Here, we hypothesized that NAFLD 
severity is associated with liver tissue cytochrome b mutations and damaged mitochondrial DNA 
(mtDNA). 
Methods: We included 252 liver specimens of NAFLD patients—in whom histological disease 
ranged from mild to severe—which were linked to clinical and biochemical information. Tissue 
molecular explorations included MT-CYB sequencing and analysis of differential mtDNA damage. 
Profiling of circulating Krebs cycle metabolites and global liver transcriptome was performed in a 
subsample of patients. Tissue levels of 4-hydroxynonenal—a product of lipid peroxidation and 8-
hydroxy-2’–deoxyguanosine and a marker of oxidative damage—were measured. 
Results: Compared to simple steatosis, NASH is associated with a higher level of MT-CYB 
variance, 12.1 vs. 15.6 substitutions per 103 bp (p = 5.5e-10). The burden of variants was 
associated with increased levels of 2-hydroxyglutarate, branched-chain amino acids, and 
glutamate, and changes in the global liver transcriptome. Liver mtDNA damage was associated 
with advanced disease and inflammation. NAFLD severity was associated with increased tissue 
levels of DNA oxidative adducts and lipid peroxyl radicals. 
Conclusion: NASH is associated with genetic alterations of the liver cellular respirasome, 
including high cytochrome b variation and mtDNA damage, which may result in broad cellular 
effects. 
Keywords: NASH; genetics; mitochondrial DNA; mutations; fibrosis; heritability; mitochondrial 
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INTRODUCTION
The progression of nonalcoholic fatty liver disease (NAFLD) into severe histological forms is 
paralleled by the occurrence of complex molecular processes that lead to a gradual loss of organ 
function and systemic metabolic derangement. Liver mitochondrial structural defects and 
mitochondrial dysfunction are the hallmark features of advanced disease [1-6]. Nonalcoholic 
steatohepatitis (NASH)—the distinctive severe histological disease form marked by the presence 
of fatty infiltration with chronic inflammation, ballooning degeneration, and different degrees of 
fibrosis [7]—is associated with molecular alterations of the liver mitochondrial DNA (mtDNA), 
including epigenetic modifications [3] and complex mitochondrial genomes with high mutational 
rate and degree of heteroplasmy [6]. We previously demonstrated that the liver of NASH patients 
presents a high variation rate in genes of the five oxidative phosphorylation (OXPHOS) protein 
complexes, i.e., respiratory complexes (Complex I−IV) and ATP synthase Complex V [6]. 
The OXPHOS system is the main source of cell energy, as the generated electrons and protons 
flow across the mitochondrial membrane. This proton gradient is used for ATP synthesis. All 
aforementioned components of the OXPHOS complex participate in the cellular respiratory 
process, but four of the OXPHOS protein complexes (I to IV) associate into stable entities called 
respiratory supercomplexes [8,9]. In mammalian mitochondria, almost the entire Complex I is 
coupled with Complex III and up to four copies of Complex IV, and this network of respiratory 
chain complexes is known as respirasome [9]. These supercomplexes exhibit a stabilizing role in 
each sub-module of the respiratory complex [10],  and the mitochondrially-encoded cytochrome B 
(cytochrome b, MT-CYB)—also known as Complex III Subunit III or cytochrome b-c1 complex or 
ubiquinol-cytochrome c reductase complex, is a key component of the respirasome [8,9]. 
Mutations of the MT-CYB gene and/or mtDNA damage at the cytochrome b region may lead to 
severe respirasome supercomplex deficiency, and eventually to cell death in tissues that require 
abundant energy supply [8,9,11]. Reactive oxygen species (ROS)-promoting mutations in 
Complex III have also been implicated in a range of metabolic disorders [11]. 
Here, we hypothesized that NAFLD severity may be driven by the accumulation of genetic 
alterations of the mitochondrially-encoded cytochrome b within the liver tissue, including a high 
mutation rate and the presence of mtDNA lesions. We reasoned that exploring tissue effects across 
different histological stages of disease severity, as well as diverse phenotypic environments, would 
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Therefore, we examined 252 liver specimens linked to clinical and biochemical information. We 
further sequenced the MT-CYB gene, and we explored the presence of tissue-damaged mtDNA. In 
addition, we assessed the potential global metabolic effects of these molecular changes.
SUBJECTS AND METHODS 
Study design and patient selection criteria, and physical, anthropometric, and biochemical 
evaluation 
Participants were selected from two different hospital-based settings, including a cross-sectional 
study of adult overweight/obese individuals patients diagnosed with NAFLD and features of the 
Metabolic Syndrome (MetS) in the Liver Unit, Hospital Abel Zubizarreta, Buenos Aires, 
Argentina, and an independent cohort of adult morbidly obese patients with NAFLD that 
underwent bariatric surgery in the Surgery Department, Hospital de Alta Complejidad en Red El 
Cruce, Buenos Aires, Argentina. 
Inclusion criteria: patients were considered for inclusion only if they presented: 1) 
histopathological evidence of NAFLD, either nonalcoholic fatty liver (NAFL) or NASH, based on 
a liver biopsy conducted within the study period, and 2) available DNA isolated from the liver 
tissue to perform molecular explorations as explained in the Supplementary Appendix, which 
was the limiting inclusion factor. 
Overweight/obese individuals patients diagnosed with NAFLD were offered a percutaneous liver 
biopsy if they show either abnormal aminotransferase levels (alanine and/or aspartate 
aminotransferase defined as >41 U/L), gamma-glutamyl-transferase > 50 U/L, alkaline 
phosphatase > 250 UI/L, and/or severe insulin resistance (HOMA-IR value greater than 3). 
In the case of morbidly obese cohort (bariatric surgery cohort), surgically excised liver samples 
were performed to all consecutive patients attending the Surgery Department, Hospital de Alta 
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Liver specimens of patients without NAFLD were included as a part of the molecular 
explorations. Further details can be found in the Supplementary Appendix.
 All participants (NAFLD patients and non-NAFLD patients) were selected during the same study 
period from the same population of patients attending the Liver Unit, and all of them share the 
same demographic characteristics (occupation, educational level, place of residence, and 
ethnicity). Adopting a case-control design, we ensured that the control liver samples matched 
patients’ features in each cohort (morbidly obese and non-morbidly obese). 
The exclusion criteria were secondary causes of steatosis, including alcohol abuse (≥30 g alcohol 
daily for men and ≥20 g for women), total parenteral nutrition, hepatitis B and hepatitis C virus 
infection, and the use of drugs known to precipitate steatosis. By using standard clinical and 
laboratory evaluation, as well as liver biopsy features when applicable, autoimmune liver disease, 
metabolic liver disease, Wilson’s disease, and -1-antitrypsin deficiency were likewise ruled out 
in all patients. 
See cohorts, participants, and analyses flow chart in Supplementary Figure 1. Biological samples 
from all participants were obtained with written informed consent following Institutional Review 
Board-approved protocols (protocol number: 104/HGAZ/09, 89/100, and 1204/2012). All the 
investigations performed in this study were conducted in accordance with the guidelines of the 
1975 Declaration of Helsinki. Complete details regarding liver biopsy and histopathological 
evaluation, immunohistochemistry (IHQ), MT-CYB sequencing, tissue MT-CYB damage, serum-
targeted TCA cycle metabolite profiling, gene expression profiling of the whole liver 
transcriptome and enrichment analysis, and statistical analysis are provided in the Supplementary 
Appendix. The primer sequences are shown in Supplementary Table 1 and 2. 
RESULTS
The clinical and biochemical features of NAFLD and non-NAFLD patients are shown in Table 1 
and Supplementary Table 3, respectively. The comparison between non-morbidly obese patients 
with NAFLD (NAFL and NASH), among whom histological features were obtained by 
percutaneous liver biopsy versus morbidly obese patients with NAFLD (NAFL and NASH), of 
whom histological features were obtained by surgical biopsy during bariatric surgery is shown in 
Supplementary Table 4.   
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Analysis of nucleotide changes in the amplified MT-CYB gene fragment per each individual 
enrolled in this study was performed based on the alignment with the reference sequence 
(NC_012920.1 Reference assembly). Median number of cumulative MT-CYB variants/mutations 
in the liver tissue (median 10, mean 12.56, range 5−66) was further used to perform the analysis of 
dichotomous phenotypes, such as high and low cumulative number of MT-CYB variants and 
variables of interest. Supplementary Figure 2 shows representative sequence electropherograms 
sequenced by Sanger as an example. 
The comparison of MT-CYB genetic variability in the liver of NAFL (12.1 variants per 1000 bp) 
vs. NASH patients (15.6 variants per 1000 bp) showed that the disease severity is associated with 
a high mutation/variation (p = 5.5e-10) rate; cumulative OR 1.30, 95% CI: 1.19−1.41. Likewise, 
analysis of liver MT-CYB sequencing revealed that the cumulative number of variants was 
associated with histological features, including the histological degree of steatosis (p = 3.0e-4), the 
lobular inflammation score (p = 8.0e-3), and the NAS score (p = 3.0e-2). Besides, cumulative 
number of MT-CYB mutations in liver tissue was associated with aminotransferases (ALT p = 
1.9e-2 and AST p = 1.5e-2), alkaline phophatase (p = 1.0e-10), and lactic acid (p = 2.2e-2) levels.
We further explored phenotypic features that may influence the genetic diversity of MT-CYB and 
found an inverse relationship between the cumulative number of MT-CYB variants and body mass 
index (BMI) (Spearman R -0.40, p = 1.0e-10). The number of cumulative variants in the liver of 
morbidly obese NAFLD patients (either NAFL or NASH) was significantly lower than that 
obtained for NAFLD overweight/obese individuals (Post-hoc test for linear trend p = 0.0007 Slope 
-1.04). The number of MT-CYB cumulative variants according to BMI status (morbidly obese vs. 
overweight/obese patients) and stages of the disease severity is shown in Supplementary Figure 
3. No association was found between the cumulative number of MT-CYB variants and fasting 
glucose, insulin, HOMA-IR, and hemoglobin A1c. Complete details for every MT-CYB variant, 
including nucleotide position, reference SNP (rsid) identification number, alleles, gene 
consequence, PolyPhen prediction (if available), SIFT prediction (if available), and clinical 
significance (if available) are shown in Supplementary Table 5. 
Rare mutations reported as pathogenic
Using the sequencing approach described above, we searched for rare—either homoplasmic or 
heteroplasmic MT-CYB—mutations already reported as pathogenic in the MITOMAP 
(http://www.mitomap.org), OMIN (Online Mendelian Inheritance in Man), and/or CLINVAR 
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three missense (m.G14846A, m.G15092A, and m.T15237C) and one nonsense- stop gained 
(m.G15242A)—and one rare (m.G15077A) homoplasmic mutation (Figure 1AB and 
Supplementary Table 6). In previous studies, these mutations were shown to impair the 
enzymatic function of the respiratory-chain cytochrome b protein (Supplementary Table 6). The 
patient carrying the homoplasmic m.G15077A mutation was a 33-year-old woman presenting with 
NAFLD and severe (BMI 53) obesity. None of the patients in this series had symptoms of 
neuromuscular and/or extra-hepatic disorders, except for the NASH patient carrying the 
heteroplasmic stop gained m.15242 mutation, who presented with progressive muscle weakness 
and pain, recurrent headaches, and vomiting. Liver MT-CYB protein expression levels in the 
patient carrying the nonsense mutation were severely decreased (Figure 1C). 
Tissue-damaged mtDNA at cytochrome b region occurred more often among severely obese 
patients with advanced disease
DNA damage or DNA fragmentation may reduce the amount of amplifiable templates; therefore, 
sequencing of fragmented DNA might result in loss of damaged DNA sites and might induce 
amplification bias in such a way that the sequenced fragments contain missing or underrepresented 
loci information [12]. Therefore, we reasoned that the inverse association between the cumulative 
number of MT-CYB variants in the liver tissue and BMI might be explained by the presence of 
lesions and/or breaks in the mtDNA. To test this hypothesis, we assessed the presence of liver MT-
CYB damage by a validated quantitative-PCR method, which relies on the relative amplification of 
a short and a long fragment in the same region. We found that long and short fragments were 
amplified with comparable efficiencies, 2.064 and 1.954, respectively. 
The analysis of cytochrome b lesions revealed a significant and positive association between liver 
MT-CYB damage and BMI (p = 7.9e-5); logistic regression OR for mtDNA damage over the 
median: 1.04 95% CI: 1.02−1.07, p = 6.6e-4. In addition, the differential level of MT-CYB 
damage, which was more pronounced in the group of morbidly obese patients, was significantly 
associated with the disease severity (p = 1.0e-3) (Figure 2A). There was a significant (p = 4.9e-2) 
interaction between disease severity (NASH vs. NAFL) and population sample 
(overweight/moderately obese vs. morbidly obese patients), even after adjusting for age, sex, and 
HOMA index.
Liver MT-CYB damage was also significantly associated with lobular inflammation (p = 6.5e-3). 
This association remained significant in the group of morbidly obese NAFLD patients (p = 1.0e-3) 
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the presence of liver MT-CYB damage and age, sex, history of type 2 diabetes, and/or any 
biochemical parameters, including glucose, insulin, or lipid-related traits.   
The burden of liver MT-CYB variants is associated with circulating levels of metabolites
In a subsample of patients (n = 22), we explored the circulating level of Krebs cycle metabolites to 
test the hypothesis that the increased number of liver mutations in a component of the cellular 
respirasome supercomplex might induce global metabolic changes. We classified NAFLD patients 
into two groups based on the median cumulative number of MT-CYB variations (<10 and ≥10). 
We found that the burden of liver MT-CYB diversity was significantly associated with circulating 
levels of 2-hydroxyglutarate, branched-chain amino acids, and glutamate, among other metabolites 
(Figure 2B). 
NAFLD severity is associated with increased tissue levels of DNA oxidative adducts and lipid 
peroxyl radicals
We hypothesized that the liver tissue of patients with more severe histological disease presents 
increased levels of products of oxidative damage and lipid peroxidation, which would make 
mtDNA more susceptible to damage and mutation. To test this hypothesis, we measured 8-OHdG 
and 4-HNE levels by IHQ in the tissue samples of patients showing the full spectrum of NAFLD 
severity, as well as in the liver tissue of patients without evidence of NAFLD. 
8-OHdG immunoreactivity product was significantly associated with the disease severity (linear 
test for trend p < 0.0001) (Figure 3A-C and Supplementary Figure 4A). Specifically, 8-OHdG 
immunostaining level was detected at the highest levels in the liver of NASH patients (Figure 
3A), whereas it was low in the liver of NAFL patients (Figure 3B) and negligible in control (non-
NAFLD) tissue samples (Figure 3C). 8-OHdG–positive immunostaining was seen at both nuclear 
and cytoplasmic localization, which is expected because the 8-OHdG detection method stains 
nuclear DNA and mtDNA as well. Likewise, we found that the cumulative number of MT-CYB 
mutations was significantly and positively correlated with tissue levels of 8-OHdG (R 0.86, p = 
4.0e-5).  
Furthermore, we found that, compared with NAFL and non-NAFLD, tissue levels of 4-HNE were 
significantly higher in patients with NASH (Figure 3D-F and Supplementary Figure 4B). 4-
HNE immunoreactivity product was significantly increased in a disease-severity grade-dependent 
manner from non-NAFLD (control) to NAFL to NASH (linear test for trend p = 0.0007), as shown 
Figure 3D-F. 4-HNE immunostaining was exclusively localized in the cell cytoplasm, including 
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of 4-HNE are also present in inflammatory cells (Figure 3D). Moreover, the cumulative number 
of MT-CYB mutations was significantly and positively correlated with tissue levels of 4-HNE (R 
0.66, p = 2.0e-2). 
Impact of the cumulative number of MT-CYB mutations/variation on the whole liver 
transcriptome
In view of the numerous roles that mitochondria play in metabolically active tissues, we reasoned 
that multiple mutations in a member of the respirasome supercomplex would be associated with 
broad perturbations of cellular physiology, including changes in the full range of gene expression. 
To assess the difference in gene expression according to the cumulative number of liver MT-CYB 
mutations, we explored the entire liver transcriptome.
The comparison between tissue samples of NAFLD patients with the highest cumulative number 
of MT-CYB mutations and the reference group (low number of cumulative mutations) showed 
3291 up-regulated and 1817 down-regulated transcripts with a FDR > 0.01. The most significantly 
differentially expressed genes are shown in Supplementary Table S7. Overrepresentation 
analysis (ORA) of genes exhibiting significantly differential expression was carried out to identify 
the biological processes and KEGG pathways most severely affected by the high MT-CYB 
mutational profile. The analysis based upon significantly up-regulated transcripts showed 
enrichment of pathways associated with epigenetic (chromatin and chromosome organization) and 
post-translational (serine phosphorylation) modifications, regulation of intracellular signal 
transduction, and cell cycle and migration (Figure 4 and Supplementary Table S8). Analysis 
based upon significantly down-regulated transcripts showed the enrichment of expected processes 
affected by OXPHOS chain failure, such as striated muscle contraction, as well as many critical 
metabolic processes, including cholesterol biosynthesis, metabolism of steroids, drug response, 
organic hydroxy compound metabolic process, and secondary alcohol metabolic process, which 
includes isocitrate (an important intermediate in the TCA), ergosterol (the most important of the D 
provitamins that is converted to vitamin D2 upon irradiation with UV light) and vitamin D3 
metabolic processes (Figure 5 and Supplementary Table S9).
DISCUSSION
Complex III of the mitochondrial respiratory chain is central to the cellular energy production 
process. It is also the main site of ROS production, which may lead to high level of DNA damage. 
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cumulative number of variants and mtDNA lesions of the mitochondrially-encoded cytochrome b 
gene. The most remarkable feature of the present study is that molecular explorations were 
performed in a relatively large collection of tissue samples of NAFLD patients, which allowed us 
to infer a direct impact on the disease. We found that NASH, as well as features of the disease 
severity, including severe inflammation, were associated with high MT-CYB mutation/variation 
rate in the liver. The potential detrimental consequences of the high liver cytochrome b gene 
mutation rate seem not to be limited to the severity of histological features, as it might also affect 
global metabolic functioning. In the analyzed samples, the burden of MT-CYB diversity was 
significantly associated with circulating levels of alpha-ketoglutarate/pyruvate ratio, branched-
chain amino acids, glutamic acid, and 2-hydroxyglutaric acid, which are known predictors of 
metabolic risk [13,14] and hepatic carcinogenesis [15]. Furthermore, we found that the cumulative 
number of MT-CYB variants was inversely correlated with BMI, which may be explained by the 
presence of increased mtDNA damage in morbidly obese patients. 
Perturbations of mtDNA integrity and increased mutations in the mtDNA are probable 
consequences of oxidative injury. We found significantly increased tissue levels of DNA oxidative 
adducts (8-OHdG) and lipid peroxyl radicals (4-HNE). Our results are supported by earlier 
observations showing that (i) ROS [16] and lipid peroxidation products [17] can damage mtDNA 
via oxidation of guanosine to 8-OHdG and release of 4-HNE—one of the most bioactive lipid 
alkenals, respectively; (ii) oxidative stress-induced lesions in mtDNA can lead to somatic 
mutations that accumulate, affect the integrity of respiratory chain, and cause mitochondria-
dependent degenerative diseases and cancer [16,18]; (iii) production of 8-OHdG is also an 
indicator of the presence of single-strand breaks [19]; and (iv) mitochondria are regarded as the 
major cellular site for ROS and 4-HNE formation [20], the latter presumably by oxidation of 
abundant PUFA-containing lipids [18]. It has also been suggested that mtDNA may serve as a 
sentinel molecule linking oxidative damage to inflammation in parenchymal cells [21]. Seki and 
coworkers reported that oxidative cellular damage occurs frequently in NASH, positing that it may 
be associated with liver fibrosis and possibly hepatocarcinogenesis [22]. Likewise, results yielded 
by experimental and human studies showed that the release of mitochondrial DNA molecules to 
the cytosol or the extracellular space triggers a pro-inflammatory response [23]. 
Finally, we found that the high MT-CYB mutation rate was associated with a wide range of 
perturbations in pathways that are linked to cancer development and metabolic deregulation. 









This article is protected by copyright. All rights reserved
associated with epigenetic modifications and perturbations of cell cycle and migration, which is 
consistent with the concept that primary impairment of mitochondrial function via mtDNA 
mutations is a pervasive feature of cancer [24]. The enrichment analysis of a set of down-regulated 
genes identified pathways associated with cholesterol biosynthesis, particularly the transformation 
of zymosterol into cholesterol, which serves as the source of the 7-dehydrocholesterol for the 
synthesis of vitamin D. 
It is worth emphasizing that mutations in any member of the OXPHOS chain can affect the 
functionality and operational capacity of the overall respiratory chain because the OXPHOS 
operates as one functional unit [25]. In fact, we have demonstrated that the expression of 
OXPHOS genes in the liver tissue is highly correlated [6]. 
It is also noteworthy that we found five likely pathogenic—either heteroplasmic or 
homoplasmic—MT-CYB mutations. To our knowledge, this is the first report concerning 
pathogenic mutations in this locus associated with NAFLD. 
Each of the rare mutations reported here is reported as associated with multisystemic disorders, 
such as mitochondrial encephalomyopathy, stroke-like episodes (the MELAS syndrome), 
maternally inherited or aminoglycoside-induced deafness, exercise intolerance, cardiomyopathy, 
and/or liver failure [26-28]. Hitherto, mitochondrial hepatopathies have been regarded as primarily 
occurring in early childhood [27], with some of the affected children presenting with hepatic 
steatosis [26,27]. 
Our results suggest that NAFLD in patients carrying respiratory-chain Complex III mutations in 
the liver tissue might be regarded as a mitochondrial hepatopathy. This is consistent with the 
notion that mutations in the mitochondrial genome may lead to progressive chronic degenerative 
processes, including tissue aging and organ damage. However, direct confirmation of pathogenesis 
on mtDNA at the cell and/or tissue level is needed to fully understand the impact of the above 
mentioned observations on NAFLD disease severity. The nature of our study, which included 
biological samples obtained by an invasive method (liver biopsy), justifies the methodological gap 
that exists between cause and effect in our findings. Isolation of mitochondria from fresh liver 
tissue to perform, for example, blue-native polyacrylamide gel electrophoresis for supercomplex 
analyses is technically challenging in human biological samples because it demands considerable 
amount of tissue.   
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Although our results based on the transcriptome and metabolic profiling are exploratory given the 
modest sample sizes on which the sub-studies were performed, there is remarkable consistency in 
the observations yielded, suggesting that an increased number of tissue mutations in the 
mitochondrial cytochrome b promotes a metabolic and cellular environment that generates 
oncogenic metabolites and initiates tumorigenesis. This mechanism might explain the 
development of de novo hepatocellular carcinoma in NASH patients. Nevertheless, future 
investigations will be needed to further explore the possibility of causal relationships among our 
findings.       
In summary, much progress has been made to understand the NASH pathogenesis. Disease 
mechanisms involving loss of mtDNA integrity are critical not only because mtDNA is essential 
for mitochondrial function maintenance, but also because mtDNA regulates cell physiology. Our 
results highlight a novel pathogenic mechanism for understanding NAFLD severity, which may 
occur as the consequence of genetic alterations of the liver cellular respirasome, including 
respiratory-chain Complex III genetic instability and mtDNA damage. The impact of MT-CYB 
genetic variability on NAFLD severity seems not to be related to only the number of variants in 
MT-CYB, but to the cumulative effects on the disease states.
Ultimately, NAFLD may exhibit the whole spectrum of a complex disease, from Mendelian 
syndrome-associated, to the classical polygenic and multifactorial and mitochondrial forms.        
Conflict of interest: 
Nothing to declare.
Authors’ contributions: 
 CJP and SS designed research (project conception, development of overall research plan, and 
study oversight); CJP, DF, SS conducted research (hands-on conduct of the experiments and data 
collection); CJP, SS analyzed data or performed statistical analysis; CJP, MG, GOC, SS 
performed liver biopsies and/or collected biological specimens; CJP and SS wrote paper; CJP and 










This article is protected by copyright. All rights reserved
References
[1] Caldwell SH, de Freitas LA, Park SH, et al. Intramitochondrial crystalline inclusions in 
nonalcoholic steatohepatitis. Hepatology 2009; 49(6): 1888-95.
[2] Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in 
humans with non-alcoholic Fatty liver is lost in steatohepatitis. Cell Metab 2015; 21(5): 
739-46.
[3] Pirola CJ, Gianotti TF, Burgueno AL, et al. Epigenetic modification of liver mitochondrial 
DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013; 
62(9): 1356-63.
[4] Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: 
association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 
120(5): 1183-92.
[5] Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in 
nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-
activated receptor gamma coactivator 1alpha promoter. Hepatology 2010; 52(6): 1992-
2000.
[6] Sookoian S, Flichman D, Scian R, et al. Mitochondrial genome architecture in non-
alcoholic fatty liver disease. J Pathol 2016; 240(4): 437-49.
[7] Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis 
Primers 2015; 1: 15080.
[8] Chaban Y, Boekema EJ, Dudkina NV. Structures of mitochondrial oxidative 
phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys 
Acta 2014; 1837(4): 418-26.
[9] Schagger H, Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian 










This article is protected by copyright. All rights reserved
[10] Lobo-Jarne T, Ugalde C. Respiratory chain supercomplexes: Structures, function and 
biogenesis. Semin Cell Dev Biol 2018; 76: 179-90.
[11] Acin-Perez R, Bayona-Bafaluy MP, Fernandez-Silva P, et al. Respiratory complex III is 
required to maintain complex I in mammalian mitochondria. Mol Cell 2004; 13(6): 805-15.
[12] Baumer C, Fisch E, Wedler H, Reinecke F, Korfhage C. Exploring DNA quality of single 
cells for genome analysis with simultaneous whole-genome amplification. Sci Rep 2018; 
8(1): 7476.
[13] Sookoian S, Castano GO, Scian R, et al. Serum aminotransferases in nonalcoholic fatty 
liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs 
cycle level. Am J Clin Nutr 2016; 103(2): 422-34.
[14] Yin X, Subramanian S, Willinger CM, et al. Metabolite Signatures of Metabolic Risk 
Factors and their Longitudinal Changes. J Clin Endocrinol Metab 2016; 101(4): 1779-89.
[15] Tompkins SC, Sheldon RD, Rauckhorst AJ, et al. Disrupting Mitochondrial Pyruvate 
Uptake Directs Glutamine into the TCA Cycle away from Glutathione Synthesis and 
Impairs Hepatocellular Tumorigenesis. Cell Rep 2019; 28(10): 2608-19.
[16] Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA 
during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad 
Sci U S A 1990; 87(12): 4533-7.
[17] Esterbauer H, Eckl P, Ortner A. Possible mutagens derived from lipids and lipid 
precursors. Mutat Res 1990; 238(3): 223-33.
[18] Zhong H, Yin H. Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: 
focusing on mitochondria. Redox Biol 2015; 4: 193-9.
[19] Toyokuni S, Sagripanti JL. Association between 8-hydroxy-2'-deoxyguanosine formation 











This article is protected by copyright. All rights reserved
[20] Liu W, Porter NA, Schneider C, Brash AR, Yin H. Formation of 4-hydroxynonenal from 
cardiolipin oxidation: Intramolecular peroxyl radical addition and decomposition. Free 
Radic Biol Med 2011; 50(1): 166-78.
[21] Szczesny B, Marcatti M, Ahmad A, et al. Mitochondrial DNA damage and subsequent 
activation of Z-DNA binding protein 1 links oxidative stress to inflammation in epithelial 
cells. Sci Rep 2018; 8(1): 914.
[22] Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of 
lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J 
Hepatol 2002; 37(1): 56-62.
[23] Garcia-Martinez I, Santoro N, Chen Y, et al. Hepatocyte mitochondrial DNA drives 
nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest 2016; 126(3): 859-64.
[24] Gammage PA, Frezza C. Mitochondrial DNA: the overlooked oncogenome? BMC Biol 
2019; 17(1): 53.
[25] Dudkina NV, Kouril R, Peters K, Braun HP, Boekema EJ. Structure and function of 
mitochondrial supercomplexes. Biochim Biophys Acta 2010; 1797(6-7): 664-70.
[26] Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the 
cytochrome b gene of mitochondrial DNA. N Engl J Med 1999; 341(14): 1037-44.
[27] Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. 
Hepatology 2007; 45(6): 1555-65.
[28] Meunier B, Fisher N, Ransac S, Mazat JP, Brasseur G. Respiratory complex III 
dysfunction in humans and the use of yeast as a model organism to study mitochondrial 










This article is protected by copyright. All rights reserved
FIGURE LEGENDS
Figure 1
Electropherograms of the MT-CYB sequencing from liver samples exhibiting rare 
pathogenic mutations
A. Heteroplasmic mutations and homoplastic mutations missense mutations. Arrow indicates the 
location of the base changes; complete details are shown in Supplementary Table 2. B. 
Heteroplasmic stop gained mutation. C. Immunohistochemical staining for MT-CYB (mutated and 
normal protein) in the liver tissue of NAFLD. 
Figure 2
Tissue-damaged mtDNA and circulating metabolites
A. Analysis of differential liver mtDNA damage at cytochrome b region assessed by semi-long 
run real-time PCR method in NAFLD patients (morbidly obese n = 65: NAFL n = 42, NASH n = 
23; non-morbidly obese n = 127: NAFL n = 56, NASH n = 71). Longitudinal axis stands for the 
extent of differential mtDNA damage, which was calculated as the inverse of the ratio obtained by 
normalizing amplification of the long mtDNA fragment with that of the short mtDNA fragment 
(ΔCp long fragment/short fragment). Statistical significance of the differences between groups was 
evaluated using Mann–Whitney U test. 
B. Circulating level of metabolites of the Krebs cycle according to the cumulative number of MT-
CYB variants (<10 and ≥10). To avoid any bias due to differentially amplified DNA lesions during 
sequencing, we based the classification of the cumulative number of MT-CYB variations on the 
sample of NAFLD overweight/obese patients. Statistical significance of the differences between 
groups was evaluated using Mann–Whitney U test. 
Figure 3
Immunohistochemical staining for 8-OHdG and 4-hydroxynonenal (4-HNE) in the liver 
tissue 
8-OHdG and 4-HNE staining in NASH (A, D), NAFL (B, E), and non-NAFLD (C, F) patients (n 
= 8 per group). Asterisk indicates area shown at higher magnification in the inset (4× 
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Impact of the cumulative number of MT-CYB mutations/variation on the whole liver 
transcriptome: significantly up-regulated genes
Volcano plot based upon functional enrichment of significantly up-regulated genes of the global 
transcriptome. Analysis of differentially expressed pathways was based on the comparison 
between NAFLD patients with high cumulative number (≥10) of MT-CYB mutations/variants 
versus the reference group (low number of cumulative mutations, i.e., <10). Enrichment method: 
ORA (over-representation analysis). Further details are shown in Online Supporting Material.
Figure 5
Impact of the cumulative number of MT-CYB mutations/variation on the whole liver 
transcriptome: significantly down-regulated genes
Volcano plot based upon functional enrichment of significantly down-regulated genes of the 
global transcriptome. Analysis of differentially expressed pathways was based on the comparison 
between NAFLD patients with high cumulative number (≥10) of MT-CYB mutations/variants 
versus the reference group (low number of cumulative mutations, i.e., <10). Enrichment method: 
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Table 1  







NAFLD overweight / obese patients
Number of subjects 56 71 -
Female (%) 53 67 NS
Age, years 55±11 54±10 NS
BMI (body mass index), kg/m2 31±5 32±5 NS
Fasting plasma glucose, mg/dL 101±22 123±43 0.0007
Fasting plasma insulin, μU/ml 13±8 16±10 0.06
HOMA-IR (homeostatic model 
assessment) index 3.3±2
4.7±4.3 0.02
HbA1c 6.5±1.5 7.7±2.5 0.0019
Total cholesterol, mg/dL 202±41 208±49 NS
HDL-cholesterol, mg/dL 52±17 50±14 NS
LDL-cholesterol, mg/dL 124±36 129±41 NS
Triglycerides, mg/dL 152±75 173±105 NS
ALT, U/L 35±17 79±57 0.0001
AST, U/L 50±34 52±33 NS
Degree of steatosis (0-3) 1.6±0.7 2.2±0.7 0.0001
Lobular inflammation (0-3) 0.6±0.7 1.2±0.7 0.0001
Hepatocellular ballooning (0-2) 0.04±0.2 1±1 0.0001
Fibrosis Stage 0 1.6±1.3 0.0001
NAFLD activity score (NAS) 2.6±1.3 4.3±2 0.0001
NAFLD morbidly obese patients
Number of subjects 42 23 -
Female, % 67 67 NS
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BMI, kg/m2 52±12 48±11 NS
Fasting plasma glucose, mg/dL 108±34 140±68 0.01
Fasting plasma insulin, μU/ml 13±7 29±47 0.03
HOMA-IR index 3.3±1.8 16±43 0.03
Hemoglobin A1c (glycated 
hemoglobin) 6.6±1.4
6.8±1.8 NS
Total cholesterol, mg/dL 182±38 185±54 NS
HDL-cholesterol, mg/dL 46±10 40±7.5 0.01
LDL-cholesterol, mg/dL 127±27 132±45 NS
Triglycerides, mg/dL 146±52 193±110 0.022






Degree of steatosis, % 1.6±0.8 2.2±0.7 0.0037
Lobular inflammation (0-3) 0.3±0.6 1.5±0.9 0.0001
Hepatocellular ballooning (0-2) 0.16±0.4 1±0.6 0.0001
Fibrosis Stage 0.02±0.2 1.5±1.3 0.0001
NAFLD activity score (NAS) 2±1.3 5±1 0.0001
Results are expressed as mean±SD. P-value stands for statistical significance using the Mann-
Whitney U test, except for female/male proportion that p-value stands for statistical significance 
using the Chi-square test.  
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